How cell-penetrating peptides fooled everyone

Credit: Courtesy of Margus Pooga" /> Credit: Courtesy of Margus Pooga Controversy still surrounds how certain cationic peptides enter the cell, spurred in part by this paper.1 The so-called cell-penetrating peptides (CPPs), which include short fragments of Tat from HIV-1, appeared to cross plasma membranes directly. This was surprising because the heavily arginated Tat is not the kind of molecule one often sees getting past

Written byBrendan Maher
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Controversy still surrounds how certain cationic peptides enter the cell, spurred in part by this paper.1 The so-called cell-penetrating peptides (CPPs), which include short fragments of Tat from HIV-1, appeared to cross plasma membranes directly. This was surprising because the heavily arginated Tat is not the kind of molecule one often sees getting past hydrophobic membranes. Kamran Melikov, then a postdoc at the US National Institute of Child Health and Human Development, says he was also surprised that most studies had been done in fixed cells. "It looked counterintuitive to me to use a fixation protocol."

His lab, headed by Leonid Chernomordik, and a CNRS group at the University of Montpellier headed by Bernard Lebleu, showed that fixation and incomplete washing were responsible for the artifact with Tat and a nine-arginine fragment. Uptake was largely due to endocytosis, they suggested, which means any drug conjugated to such a peptide would ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies